Radiopharmaceuticals Gold Rush: Why Novartis and Lilly Are Racing to Buy Theranostics.
Generating visualization...
Radiopharmaceuticals Gold Rush: Why Novartis and Lilly Are Racing to Buy Theranostics.
This report explores the aggressive investment pursuits of major pharmaceutical companies in the field of radiopharmaceuticals, focusing on Novartis and Lilly. It delves into the strategic moves by these companies to capture significant market share in precision oncology and theranostics. The report outlines the growth potential of this field, driven by advances in personalized medicine and a growing demand for targeted cancer therapies. It also examines the impact of recent mergers and acquisitions in shaping the industry landscape, along with regulatory and reimbursement challenges that influence market expansion.
Oncology InvestmentsPharma M&APrecision MedicineRadiopharmaceuticalsTheranosticsmedical isotopesradioligand therapy
Elsayed Abdelwadod, Ghost Research
2026-03-27
Feedback
Limited Time Offer
$50$150
(exclusive of tax)Single User License© 2025 Caspr Research Private Limited
95Pages of Deep Analysis
86Credible Sources Referenced
9Data Analysis Tables
6Proprietary AI Visuals
Elsayed Abdelwadod
7+ Years of Experience
Sectors & Industries
Information Technology
Functions & Expertise
Healthcare & Life SciencesMarket Intelligence
Perspective.
PurposeTo analyze investment strategies in radiopharmaceuticals and their impact on the healthcare industry.
AudienceIndustry analysts, healthcare investors, pharmaceutical companies, and policy makers.
Report LengthComprehensive.
Focus Areas.
Industries JobsPharmaceuticals, oncology, healthcare investment.
Geographic AreasGlobal with a focus on the US, Europe, and Asia.
Special EmphasisInnovation and strategic M&A activities.
Report Layout.
Introduction: What Is Theranostics?
- Investor-centric definition of theranostics
- Key differentiators
- Radioisotope landscape
- Economic rationale for pharma’s interest
Market Landscape & Size
- Global market size and growth forecasts
Get the Insights You Need — Download Now.
Insights.
Theranostics is evolving from single-asset trades to platform-based investments.Manufacturing capability is crucial for gaining market advantage in radiopharmaceuticals.Integration of diagnostics and therapeutics is key to future oncology strategies.Early investments are benefiting from M&A activities with high premiums.Expansion in the sector is driven by regulatory changes and demand for targeted therapies.Key Questions Answered.
